Big Buttons

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

• PCF awards state association CE grants 

  The Pharmacy Compounding Foundation has awarded $1,500 grants to eight state pharmacy associations. read more →

• Compounding vs. counterfeit — ABC News gets it

  When ABC News wanted to do a story on compounded GLP-1s, it turned to APC. Of course. read more →

• No no, Novo!

  Novo Nordisk asked the FDA to put semaglutide on the Demonstrably Difficult to Compound (DDC) list, and now APC has formally responded, pulling exactly zero punches. read more →

• About that Diabetes Association statement …

  The American Diabetes Association gets a good portion of its funding from pharmaceutical companies, including Eli Lilly and Novo Nordisk. read more →

• Foundation welcomes 2025 board members

  Congratulations to the newest members of the Pharmacy Compounding Foundation Board of Directors read more →

• End Drug Shortages Act intro’d in Congress

  The legislation would expand the sources the FDA may use to declare drug shortages. read more →

More News

You’re not alone; APC has heard reports from several pharmacies that have received them.

The background: Verrica obtained FDA approval for their 0.7% topical cantharidin solution. 

The gist: This is legit. Although pharmacies have been compounding with cantharidin for decades, they can no longer prepare copies of the 0.7% solution. You can still prepare specialized cantharidin formulations (e.g., combinations with podophyllin) based on a prescriber’s order. 

Read this recommendation from the law firm Boesen and Snow on how to respond when you receive a cease and desist letter.